Angle PLC Announces Strategy Update

Rhea-AI Summary

ANGLE plc (AIM:AGL / OTCQX:ANPCY) announced a strategic refocus and management change on 8 October 2025. Dr Jan Groen moves from Non-Executive Chairman to Executive Chairman to lead a revised strategy centred on CTC intelligence and accelerated commercial traction using the Parsortix platform. The company proposes a name change to CelLBxHealth plc and an AIM ticker change to CLBX, expected mid-October.

The plan emphasises proteomics and genomics applications, tighter cost control and partnerships. Cash runway is stated through to Q1 2026, and the company expects a need to raise funds in the coming months. CEO and Finance Director will transition out over the next 12 months, with contractual entitlements honoured.

Positive

• Executive Chairman appointment of Dr Jan Groen with 25+ years' oncology diagnostics experience
• Proposed name change to CelLBxHealth to align strategy with CTC intelligence
• Strategic focus on proteomics and genomics leveraging the Parsortix CTC platform

Negative

• Cash runway confirmed only through Q1 2026
• Company expects to raise funds in the coming months
• CEO and Finance Director will transition out over 12 months

Appointment of Executive Chairman, proposed change of name and strategy update

Company to pursue revised strategy and name change to CelLBxHealth plc

Dr. Jan Groen, the current Non-Executive Chairman and recognised oncology diagnostic industry veteran, to lead company as Executive Chairman

Revised strategy to sharpen focus on the provision of industry-leading CTC intelligence and accelerate Company's commercial traction, whilst delivering further cost control

Cash runway remains through to Q1 2026; expected need to raise funds in coming months

GUILDFORD, SURREY, AL / ACCESS Newswire / October 8, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a global precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that its Chairman, Dr Jan Groen, has moved into an executive role. Jan will lead the Company as it pursues a revised strategy, focused on tight cost control, accelerated commercial progress and a clear plan towards becoming a sustainable business.

Jan has over 25 years of experience in the commercialisation of clinical and personalised oncology diagnostics, and has led the turnaround of several companies, one of them being a publicly listed company, Oncomethylome Science, that has continued successfully after its restructure as MDxHealth (NASDAQ: MDXH). Jan is working alongside the senior management team to identify the appropriate ongoing cost base whilst progressing a number of potential collaborations and partnerships that were detailed in the interim results in early September.

As part of its revised strategy, the Company proposes to change its name to CelLBxHealth plc. The new name reflects the Company's sharpened focus on 'CTC intelligence', the provision of high-value CTC-based precision diagnostic testing for the pharmaceutical services sector and the clinical diagnostics market.

The Board believes that the new name, CelLBxHealth, encapsulates the Company's aspirations. "CelLBx" (short for Circulating Tumour Cells obtained via liquid biopsy, "LBx") reflects a key and rapidly emerging field of healthcare innovation, where diagnostics and therapeutics increasingly converge. The addition of "Health" underscores the Company's core mission: to support pharmaceutical companies and clinicians in improving outcomes for cancer patients.

The initial emphasis will be on the proteomics and genomics market segment. Here the Company will seek to maximise the potential of its proprietary Parsortix platform for CTC isolation by developing applications that integrate existing proteomics and genomic assays capable of providing complementary insights to circulating tumour DNA.

The change of name is expected to take effect in mid-October, following the issuance of a Certificate of Incorporation on change of name by Companies House. The Company's AIM ticker will be CLBX.

As highlighted in the recent interim results statement, the Company has a cash runway into Q1 2026. As such, the expectation is that the Company will need to raise funds in the coming months. This process will commence once there is clarity on the appropriate cost base, funding need and a clear path to greater commercial traction.

Andrew Newland, Chief Executive, and Ian Griffiths, Finance Director have continued to provide support to the Company in their non-board roles and will be transitioning out of the business in due course. Their contractual entitlements will be honoured over the next 12 months, with no acceleration of these costs expected to affect the Company's cash runway.

For further information:

ANGLE plc	+44 (0) 1483 343434
Dr Jan Groen, Executive Chairman	investor@angleplc.com
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales)	+44 (0) 20 7220 0500
FTI Consulting Simon Conway, Ciara Martin, Sam Purewal Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014).Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For Research Use Only. Not for use in diagnostic procedures.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc

ANGLE plc is a global precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and enables comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows - supporting research, drug development and clinical oncology.

Commercial activities centre on (i) biopharma clinical services, (ii) partnerships, (iii) development of laboratory-developed tests (LDTs), and (iv) Research Use Only validation of existing commercial proteomic and genomic assays. The product portfolio comprises the Parsortix® platform with associated consumables and assays. Biopharma services are delivered from ANGLE's GCLP-compliant UK laboratory, providing bespoke LDT development, clinical-trial testing and service testing.

For more information, visit www.angleplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on ACCESS Newswire

FAQ

When will ANGLE plc change its name to CelLBxHealth and what will the new AIM ticker be?

The name change is expected to take effect in mid-October 2025, with the AIM ticker changing to CLBX.

What does ANGLE's cash runway through Q1 2026 mean for ANPCY shareholders?

The company states it has cash runway into Q1 2026 and expects to raise funds in the coming months after defining cost base and funding needs.

Who is Jan Groen and what role will he play at ANPCY after October 8, 2025?

Dr Jan Groen, an oncology diagnostics executive with over 25 years' experience, becomes Executive Chairman to lead the revised strategy.

How will ANGLE use its Parsortix platform under the new CelLBxHealth strategy?

The company will prioritise CTC isolation to develop applications that integrate proteomics and genomic assays for drug development and clinical diagnostics.

Will ANGLE accelerate commercial activity as part of the strategy update?

Yes; the revised strategy emphasises accelerated commercial traction, partnerships and tighter cost control to drive sustainability.

What happens to ANGLE's CEO and Finance Director following the announcement?

Andrew Newland (CEO) and Ian Griffiths (Finance Director) will continue in non-board roles and will transition out over the next 12 months, with contractual entitlements honoured.